Proportions and Rates of Sustained LDA Achievement with Baricitinib Treatment
| Pts achieving CDAI ≤10 | BL CDAI ≤ median | BL CDAI > median | |||||
|---|---|---|---|---|---|---|---|
| PBO | Bari 4 mg | Bari 2 mg | PBO | Bari 4 mg | Bari 2 mg | ||
| RA-BUILD | N | 116 | 108 | 114 | 108 | 116 | 111 |
| Wk12 | % | 19.8 | 42.6 | 40.4 | 7.4 | 21.6 | 18.0 |
| i-rate | 4.36 | 11.78 | 10.50 | 1.55 | 4.69 | 3.90 | |
| Wk24 | % | 44.8 | 63.9 | 63.2 | 17.6 | 41.4 | 32.4 |
| i-rate | 10.63 | 19.20 | 17.59 | 3.80 | 9.59 | 7.27 | |
| RA-BEAM | N | 249 | 236 | 235 | 246 | ||
| Wk12 | % | 23.7 | 39.8 | 4.3 | 18.7 | ||
| i-rate | 2.71 | 5.40 | 0.42 | 1.98 | |||
| Wk24 | % | 34.5 | 69.1 | 14.0 | 41.9 | ||
| i-rate | 4.35 | 12.97 | 1.49 | 5.47 | |||
Pts were defined as responders if they met the response criterion within the stated time frame, prior to any rescue or discontinuation. % = percent of pts meeting response criteria; CDAI median = 34.8 (RA-BUILD) or 36.2 (RA-BEAM); i-rate = exposure-adjusted incidence rate (% pts/month); N = number of randomised and treated pts.